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Abstract
Background: Red blood cell distribution width (RDW), an automated measure of red blood cell size heterogeneity (e.g.,
anisocytosis) that is largely overlooked, is a newly recognized risk marker in patients with cardiovascular diseases, but its
role in persistent viral infection has not been well-defined. The present study was designed to investigate the association
between RDW values and different disease states in hepatitis B virus (HBV)-infected patients. In addition, we analyzed
whether RDW is associated with mortality in the HBV-infected patients.
Methodology/Principal Findings: One hundred and twenty-three patients, including 16 with acute hepatitis B (AHB), 61
with chronic hepatitis B (CHB), and 46 with chronic severe hepatitis B (CSHB), and 48 healthy controls were enrolled. In all
subjects, a blood sample was collected at admission to examine liver function, renal function, international normalized ratio
and routine hematological testing. All patients were followed up for at least 4 months. A total of 10 clinical chemistry,
hematology, and biochemical variables were analyzed for possible association with outcomes by using Cox proportional
hazards and multiple regression models. RDW values at admission in patients with CSHB (18.3063.11%, P,0.001), CHB
(16.3762.43%, P,0.001) and AHB (14.3861.72%, P,0.05) were significantly higher than those in healthy controls
(13.0361.33%). Increased RDW values were clinically associated with severe liver disease and increased 3-month mortality
rate. Multivariate analysis demonstrated that RDW values and the model for end-stage liver disease score were independent
predictors for mortality (both P,0.001).
Conclusion: RDW values are significantly increased in patients with hepatitis B and associated with its severity. Moreover,
RDW values are an independent predicting factor for the 3-month mortality rate in patients with hepatitis B.
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Introduction
Red cell distribution width (RDW) is an automated measure of
the heterogeneity of red blood cell (RBC) sizes (e.g. anisocytosis)
and routinely performed as part of a complete blood cell counts
[1–3]. RDW is used in the differential diagnosis of anemia [4].
Recently, a series of studies have demonstrated that RDW can
serve as a novel, independent predictor of prognosis in patients
with cardiovascular diseases (e.g. heart failure [5–7], stable
coronary diseases [8], acute myocardial infarction [9], strokes
[10], and pulmonary hypertension [11]). Elevated RDW values
were also shown to be associated with increased risk of mortality in
the general population [12–14]. However, to our knowledge, the
role of RDW values in persistent viral infection has not been well-
defined. More importantly, whether RDW values are associated
with different disease states of hepatitis B virus (HBV) infection
such as acute hepatitis B (AHB), chronic hepatitis B (CHB) and
chronic severe hepatitis B (CSHB) remains unknown. The present
study was designed to investigate the association between RDW
values and different disease states in HBV-infected patients. In
addition, we analyzed whether RDW is associated with mortality
in the HBV-infected patients.
Materials and Methods
Subjects
Adult HBV-infected patients admitted to the First Affiliated
Hospital of Zhejiang University School of Medicine and diagnosed
with AHB, CHB or CSHB were consecutively recruited between
August 1, 2010 and August 1, 2011. In the present study, whereas
there were no exclusions for age/sex, patients who received any
anti-HBV agents or steroids 6 months before admission were
excluded. Patients with a concurrent infection of HCV, hepatitis D
virus, hepatitis G virus, and/or human immunodeficiency virus
and any autoimmune liver disease were also excluded. During the
same time period, age- and sex-matched healthy individuals were
recruited as controls at a patient/control ratio of 3:1.
Blood samples were collected from all HBV-infected patients
within 24 hours after admission, and blood samples were taken
from 48 healthy individuals at the time of recruitment. After
discharge, all patients were followed up monthly by phone
conversation, and every three months by patient’s visit to the
hospital. Blood samples were collected at each visit for laboratory
tests including the detection of HBsAg. Neither the technician who
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up the patients knew the diagnosis of the patients.
The study was approved by the Ethics Committee of the First
Affiliated Hospital of Zhejiang University School of Medicine, and
written informed consent for participation was obtained from each
study participant.
Clinical Diagnosis
The diagnostic criteria for AHB, CHB and CSHB were in
accordance with the 2000 Xi’an Viral Hepatitis Management
Guidelines recommended by the Chinese Society of Infectious
Diseases and Parasitology, and the Chinese Society of Hepatology,
of the Chinese Medical Association [15]. Briefly, viral hepatitis B is
classified into three major clinical types, namely AHB, CHB and
CSHB. AHB is defined as when hepatitis B surface Ag (HBsAg)-
negative conversion occurs within 6 months after the initial onset
of symptoms due to HBV infection. CHB is defined as when a
HBV carrier requires a clinical course of hepatitis B infection for
more than 6 months and may have exhibited symptoms or signs of
hepatitis and abnormal hepatic function, or with histological
changes. CSHB is defined as when there is a history of CHB or
liver cirrhosis with serum HBsAg positivity of more than 6 months
and a serum total bilirubin level of more than 10 times the normal
level (i.e. 171 mmol/L), with at least one of the following five liver
failure indexes: prothrombin activity of less than 40%, hepatic
encephalopathy, ascites, progressive reduction in liver size, and
hepatorenal syndrome. In addition, the diagnosis of liver cirrhosis
was made on the basis of clinical (e.g. physical stigmata of cirrhosis),
biochemical (e.g. decreased serum albumin and increased serum
globulin levels), and ultrasonographic or computed tomography
(e.g. nodular liver surface, coarsened echogenicity of liver
parenchyma, enlarged spleen, and/or ascites) findings [16,17].
Laboratory Methods
RDW, hemoglobin level, and mean corpuscular volume (MCV)
were determined using the XE-2100 automated hematology
analyzer (Sysmex Corp, Kobe, Japan), as one part of a complete
blood cell count. The normal reference range for RDW in the
laboratory of our hospital is 11.6% –15.0%. Serum creatinine,
serum albumin, total protein, total bilirubin and alanine transam-
inase levels were measured using the Hitachi 704 Analyzer
(Boehringer Mannheim Diagnostics), and the international nor-
malized ratio (INR) was generated by the Sysmex CA1500 full-
automatic analyzer (Sysmex Corp, Hyogo, Japan). At baseline,
demographic and clinical characteristics, including the model for
end-stage liver disease (MELD) score (with higher scores indicating
more severe illness), were collected.
MELD Score
Liver disease severity at admission was evaluated via the MELD
score, which uses the patient’s serum bilirubin and creatinine levels
and the INR for prothrombin time to predict survival. The MELD
score was calculated using the web site calculator (http://www.
mayoclinic.org/gi-rst/mayomodel7.html).
Statistical Analysis
All continuous variables were expressed as mean value 6
standard deviation (SD), and categorical data as percentages. We
used SPSS version 15.0 (SPSS, Inc., Chicago, IL) to perform
statistical procedures. The Kruskal-Wallis H test and Mann-
Whitney nonparametric U test were used for comparison between
groups. Categorical data were evaluated by the x
2-test or Fisher’s
exact test, as appropriate. A multivariable stepwise logistic
regression test was used to evaluate independent clinical param-
eters predicting mortality. The receiver operating characteristic
(ROC) curve was obtained and area under the curve (AUC) was
calculated to identify the best RDW to predict mortality in patients
with HBV infection. A value of P,0.05 was considered statistically
significant.
Results
Increased RDW Values in HBV-infected Patients
A total of 123 HBV-infected patients, 16 with AHB, 61 with
CHB, and 46 with CSHB, as well as 48 healthy individuals, were
recruited during the study period (Table 1).
The RDW values of HBV-infected patients at admission ranged
from 12.0% to 27.3%. The values in patients with CSHB patients
(18.3063.11%, P,0.001), CHB patients (16.3762.43%,
P,0.001) and AHB patients (14.3861.72%, P,0.05) were
significantly higher than those in healthy controls
(13.0361.33%). Moreover, CSHB patients had higher RDW
values than CHB and AHB patients (both P,0.001), and CHB
patients had higher RDW values than AHB patients (P,0.05)
(Figure 1).
Baseline Characteristics and Baseline Factors Related with
RDW
Patients were divided into three groups based on their RDW
values: group A (RDW #15.0%), group B (.15.0%, but ,20.0%)
and group C ($20.0%). Differences in clinical and laboratory
characteristics among the three groups of RDW are listed in
Table 2. Patients with higher values of RDW tended to be older,
were more likely to have severe liver disease, had lower levels of
hemoglobin, total protein, and serum albumin, and had higher
INR and total bilirubin. The serum creatinine, gender and MCV
were not significantly different among the three groups.
The MELD score in groups A, B, and C were 10.764.2,
15.164.7 and 19.864.4, respectively. There was a stepwise
increase in MELD scores with increasing values of RDW
(P,0.001 between groups A and B, and between groups B and
C) (Figure 2, left).
Association of RDW with 3-month Mortality in HBV-
infected Patients
The median follow-up period was 72 days (range, 21–128 days).
During the follow-up, 41 patients died, none of whom were
patients with AHB, six were with CHB and 35 were with CSHB.
There was a significantly increase in the 3-month mortality rate
following increasing RDW values, with 12.7% in group A, 35.8%
in group B and 69.6% in group C (P,0.01 between groups A and
B, and between groups B and C) (Figure 2, right).
To evaluate the values for RDW and MELD score to predict
mortality, ROC curves were drawn (Figure 3). The AUCs were
calculated as 0.84760.034 for the MELD score and 0.66460.049
for RDW (both P,0.001). When RDW and MELD were
combined, the AUC was 0.90560.019 (P,0.001). The multivar-
iate logistic regression analysis showed that only the RDW values
and MELD score were independent factors predicting mortality
rate (Table 3).
Discussion
RDW reflects the variability in circulating RBC size. It is based
on the width of the RBC volume distribution curve, with larger
values indicating greater variability [18]. RDW is elevated when
there is increased red cell destruction, or, more commonly,
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deficiency (e.g. iron, vitamin B12, or folic acid), bone marrow
depression, or chronic inflammation [19–21]. These conditions
are often present in patients with liver disease, correlate with the
severity of the disease, and are associated with a worse prognosis
[22]. In our study, patients with hepatitis B had significantly higher
RDW values compared with healthy subjects and CSHB patients
had the highest RDW values among the patients. Thus, we
speculate that this difference is an important factor that influences
the disease progression, and may present an important marker for
patients with HBV infection.
The most significant finding from our study is that increasing
RDW values can serve as an independent predictor of mortality in
HBV-infected patients. Over the past decade, the MELD score
has emerged as the most widely used model for organ allocation in
liver transplantation. This model, which includes variables related
to both liver and renal function, was implemented in the USA in
2002 and is currently being used in many countries to classify
patients with cirrhosis awaiting transplantation according to the
severity of their liver disease [23]. Our previous study reported
that the MELD score was related to the prognosis of the patients
with HBV-related acute-on-chronic liver failure [24]. In the
present study, we reported that RDW can be used for predicting
HBV-infected patients mortality, although the prediction power of
RDW was relatively lower (AUC=0.66460.049 P,0.001) than
that of MELD score (AUC=0.84760.034, P,0.001). Moreover,
combining RDW with the MELD score further added to
prediction power of predicting mortality (AUC=0.90560.019,
P,0.001). This is more relevant to patients with CSHB. The
present study included 16 patients with AHB, 61 with CHB and
46 with CSHB. It is well-known that AHB patients are relatively
less commonly observed in the clinical setting because 90–95% of
adult patients generally have a spontaneously self-limited acute
hepatitis without obvious manifestation and often develop the
convalescence period through a short-term acute phase before
they see doctors. Thus, a 3-month mortality rate is relatively low in
patients with AHB. Indeed, in the present study, we found that
none of patients with AHB died, whereas six patients with CHB
and 35 patients with CSHB died before the 3-month follow-up
period.
The mechanisms underlying the association between RDW and
severity of hepatitis and its role in predicting mortality in HBV-
infected patients are unclear. Recently, in a large unselected
cohort of patients, RDW showed a strong and graded association
Table 1. Clinical characteristics of studied subjects.
AHB
(n=16)
CHB
(n=61)
CSHB
(n=46)
Healthy controls
(n=48)
Age (year) * 39.8613.0 44.5612.1 49.9613.5 43.3610.9
Gender (male/female) 11/5 46/15 36/10 36/12
Total bilirubin (mmol/L) * 107654 65613 3046150 1265
Alanine aminotransferase (U/L) * 10276818 1116146 1236118 24611
International normalized ratio* 1.3960.44 1.1360.23 2.2361.18 0.9160.21
HBsAg positive 16 61 46 0
HBeAg positive 7 61 20 0
HBcAb IgM positive 16 0 0 0
HBV DNA positive 10 61 22 0
Mortality 0 6 35 0
*Data are expressed as mean 6 standard deviation.
AHB, Acute hepatitis B; CHB, Chronic hepatitis B; CSHB, Chronic severe hepatitis B; HBsAg, Hepatitis B surface Antigen; HBeAg, Hepatitis B e Antigen; HBcAb, Hepatitis B
core Antibody; HBV, Hepatitis B virus.
doi:10.1371/journal.pone.0037644.t001
Figure 1. The association between red cell distribution width (RDW) values and different disease states in HBV-infected patients.
Data are expressed as box plots, in which the horizontal lines illustrate the 25th, 50th, and 75th percentiles of the values of RDW. The vertical lines
represent the 5th and 95th percentiles. AHB, Acute hepatitis B; CHB, Chronic hepatitis B; CSHB, Chronic severe hepatitis B.
doi:10.1371/journal.pone.0037644.g001
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age, sex, and other haematological variables [25]. Inflammation
might contribute to increased RDW values not only by impairing
iron metabolism but also by inhibiting the production of or
response to erythropoietin or by shortening RBC survival [26,27].
Indeed, a number of studies have shown that proinflammatory
cytokines suppress erythropoietin gene expression, inhibit prolif-
eration of erythroid progenitor cells, down-regulate erythropoietin
receptor expression, and reduce erythrocyte life-span [27].
Inflammation in a HBV-infected liver is proven to be mediated
by cytokines that play a pivotal role in the pathogenesis of chronic
HBV infection [28,29]. A number of cytokines are released from
macrophages or monocytes in response to stimulation by
endotoxins, and these cytokines affect disease status [30]. We
hypothesize that the association of RDW with an increased
mortality risk may, in part, be due to an effect of inflammation on
anisocytosis and risk. Moreover, as shown in the present study, we
also found an association between RDW and the severity of the
liver disease, and patients with higher values of RDW tended to be
older, had lower levels of hemoglobin, total protein, and serum
albumin, and had higher INR and total bilirubin. Meanwhile, a
typical anemia with a high RDW was found in liver cirrhosis
principally in relation to the disease severity [31]. Several studies
of the RBC mass and plasma volume in cirrhosis have shown that
there is an expanded plasma volume in the presence of portal
hypertension, leading to low hematcrit [32], and that RBC
survival is also reduced in cirrhotic patients, especially those with
anemia, although blood loss may partly contribute to the reduced
RBC survival [33]. Hemolysis appears to be the major cause of
anemia in advanced cirrhosis, in which an enlarged spleen
sequesters and destroys blood cells efficiently, leading to macro-
normoblastic bone marrow [34].
Table 2. Clinical and laboratory characteristics among patients with different red blood cell distribution width (RDW) values at
admission.
Group A
(RDW#15.0%, n=47)
Group B
(15.0,RDW,20.0%, n=53)
Group C
(RDW$20.0%, n=23) P
RDW (%)* 13.9560.94 17.0561.41 21.7061.59 ,0.001
Age (year) * 41.8613.2 48.7612.1 54.7611.5 0.003
Gender (male/female) 39/8 44/9 16/7 0.077
MCV (fL) * 92.865.2 92.568.2 89.8613.2 0.087
Hemoglobin (g/dL) * 133.8616.3 115.6618.6 94.4621.8 ,0.001
Total Protein (g/L) * 65.766.2 61.266.1 59.065.9 ,0.001
Albumin (g/L) * 38.866.2 33.765.0 32.962.9 ,0.001
Alanine aminotransferase (U/L) * 433.16658.1 128.96143.1 66.8631.5 0.003
International normalized ratio * 1.3360.41 1.5360.47 1.9960.63 ,0.001
Creatinine(mmol/L) * 63.4614.9 65.7617.8 68.9633.5 0.544
Total bilirubin (mmol/L) * 105.76115.3 164.76140.5 250.16198.7 0.001
MELD score * 10.764.2 15.164.7 19.864.4 ,0.001
Hepatic cirrhosis (yes/no) 5/42 20/33 19/4 ,0.001
Ascites (yes/no) 2/45 12/41 18/5 ,0.001
mortality (yes/no) 6/41 19/34 16/7 ,0.01
*Data are expressed as mean6standard deviation.
MCV, mean corpuscular volume; MELD score, model for end-stage liver disease score; RDW, red cell distribution width.
doi:10.1371/journal.pone.0037644.t002
Figure 2. Comparisons of the Model for End-stage liver disease (MELD) score (left) and mortality rate (right) among patients with
different red cell distribution width (RDW) values. Patients were divided into three groups based on serum RDW values: group A (#15.0%), B
(.15.0%, but ,20.0%) and C ($20.0%).
doi:10.1371/journal.pone.0037644.g002
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and CSHB were diagnosed in accordance with the 2000 Xi’an
Viral Hepatitis Management Guidelines recommended by the
Chinese Society of Infectious Diseases and Parasitology, and the
Chinese Society of Hepatology of the Chinese Medical Association
[15]. In China, the term ‘CSHB’ is usually used for the fatal form
of chronic hepatitis, which resembles the term ‘liver failure caused
by chronic hepatitis B’’ in Western countries. Although the term is
not uniformly used globally, this chronic liver condition often
demonstrates serious clinical courses with fatal consequences.
Acute attacks may occur in some patients with CHB. Moreover,
the disease may develop into liver failure (i.e. CSHB) due to various
factors, such as HBV mutations [35,36], coinfection with other
hepatotropic viruses [37–42], over-work, alcohol overdose [43],
long-term corticosteroid treatment [44], and bacterial infections
[45], during the long course of the disease. Although the
application of newly developed drugs with an artificial liver
support system is effective in some cases, the mortality rate of
CSHB may still reach 80%–100% in patients with stage III–IV
hepatic encephalopathy [46]. For these patients, orthotopic liver
transplantation [47] might be the last option. Therefore,
identification of novel predicting biomarkers is critical in
therapeutical management for CSHB.
A few limitations warrant consideration. First, we did not
investigate the causes of elevated RDW values, such as iron or
vitamin B12 deficiency, which could confound the association
between RDW values and adverse outcome. Second, this was a
single-center study and thus our relatively small sample size may
have posed a limitation to this study. Therefore, our findings need
to be confirmed in multi-center and prospectively designed studies.
Finally, RDW values were not dynamically observed, and thus,
whether RDW values are stepwise elevated when patient’s
condition is progressively deteriorated remains unclear.
In conclusion, RDW values are significantly increased in
patients with hepatitis B and associated with the severity.
Moreover, RDW values are an independent predicting factor for
the 3-month mortality rate in patients with hepatitis B. Because
RDW values are easily attainable at no additional cost to the
routine complete blood cell counts and is highly reproducible, it
may serve as an important biomarker. The strength of RDW’s
association with mortality risk that we and others have observed
compares favorably with established risk factors. It is unknown,
however, whether the risk associated with RDW is modifiable or if
RDW itself is modified by current therapies that alter prognosis.
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